Introduction: What they say
A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published, in the 6 April 2015 issue of the journal “Nature cell biology” (the number 1 journal in “Cell biology” research with an impact factor of 20+), by Prof Tzahor E, D’Uva E, and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Repurposing the anti-allergic drug into a cardioprotective drug: Tranilast-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Tranilast, an anti-
From the significance of the study to Public health relevance:
Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from 123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs and (iv) a side-effect-free Natural product-based drug.
From research findings to Therapeutic opportunity:
This study provides, for the first time, mechanistic insights into how Tranilast [(3′,4′-dimethoxycinnamoyl) anthranilic acid (N-5′)] could aid in heart regeneration and repair.
Tranilast (brand name: Rizaben, Ao Te Min, Arenist, Garesirol, Hustigen, Krix, Lumios, Tramelas and others), by regulating the expression of its target genes, it could: (1) increase ERBB2/Her2 expression; (2) induce cardiomyocyte (CM) dedifferentiation and proliferation; and (3) cardiomyocyte (CM) redifferentiation and regeneration (fig.1). Thus, pharmacological formulations encompassing“Tranilast or its activators, either alone or in combination with other drugs,” may be used to promote cardiac dedifferentiation and regeneration.
Given the mechanistic basis of how anti-allergic drug Tranilast [3′,4′-dimethoxycinnamoyl) anthranilic acid (N-5′)] or its analogs may aid in cardiomyocyte survival and regeneration, medical practitioners and cardiologists may consider: (1) treating myocardial patients with Tranilast or its analogs(s), as it may aid in cardiomyocyte regeneration following myocardial infarction; and (2) putting into a clinical trial.
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Amount: $ 500#
Undisclosed (mechanistic insights) information: How does Tranilast increase the expression of ERBB2/Her2?
For purchase and payment details, you may reach us at email@example.com
# Research cooperation
Citation: Boominathan, L., Repurposing the anti-allergic drug into a cardioprotective drug: Tranilast-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Tranilast, an anti-
Courtesy: When you cite, drop us a line at firstname.lastname@example.org